Skip to main
ABT
ABT logo

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 41%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is forecasting an organic sales growth range of 6.0-7.0% through 2025, supported by strong performances in its Electrophysiology and Structural Heart segments, which experienced organic growth rates of 13.7% and 11.3%, respectively. The company's Established Pharmaceuticals saw a 7.1% organic increase in sales, with strong contributions from key emerging markets, highlighting its broad international footprint where approximately 60% of sales are derived. Furthermore, Abbott's commitment to dividend growth, having increased payouts for over 50 consecutive years, coupled with a robust balance sheet and the potential for strategic mergers and acquisitions, reinforces a favorable outlook for the company's long-term financial stability and growth.

Bears say

Abbott Laboratories faces a negative outlook primarily due to the significant decline in Covid-19 testing sales, dropping from $265 million in Q3'24 to $69 million in Q3'25, which has led the company to adjust its financial outlook accordingly. Additionally, the company is experiencing broader macroeconomic pressures such as inflation and foreign exchange fluctuations, further complicating its revenue projections. The continuing struggles in its Diagnostics segment, particularly in China and the impact of funding cuts for HIV tests, signal persistent operational challenges that may hinder revenue growth moving forward.

Abbott Labs (ABT) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 41% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 17 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $146.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $146.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.